Diabetic Foot
3
Pipeline Programs
6
Companies
5
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
1
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
5 companies ranked by most advanced pipeline stage
Heidelberg PharmaGermany - Ladenburg
1 program1
Application of autologous bone marrowPhase 11 trial
Active Trials
PolyNovoAustralia - Port Melbourne
1 programSynPath Acellular Dermal Matrix plus Off-loading DeviceN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
OrganogenesisBi-layered cell therapy
CelularityPDA-002
City TherapeuticsNerve Block
PolyNovoSynPath Acellular Dermal Matrix plus Off-loading Device
Clinical Trials (5)
Total enrollment: 65 patients across 5 trials
Apligraf Versus Standard Therapy in the Treatment of Diabetic Foot Ulcers
Start: Oct 2000Est. completion: Sep 2002
Phase 3Terminated
Safety, Hemodynamic Effects and Efficacy of Intramuscular PDA-002 in Subjects Who Have Diabetic Foot Ulcer With Peripheral Arterial Disease
Start: Jun 2015Est. completion: Sep 2017
Phase 2Withdrawn
Local Application of Autologous Bone Marrow Cells for Treatment of Chronic Diabetic Ulcers
40 patients
Phase 1Unknown
Analyzing Anesthetic Techniques in Diabetic Foot Amputation
Start: Jul 2024Est. completion: Dec 2024
N/ARecruiting
Randomized Clinical Study Comparing SynPath to Standard of Care in Treatment of Chronic Diabetic Foot Ulcers
Start: Jul 2022Est. completion: Feb 202425 patients
N/ATerminated
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 65 patients
6 companies competing in this space